In precision medicine, clinical decisions are becoming more complex, more time‑sensitive, and more dependent on data that is often difficult to interpret in isolation. Biomarker reports, evolving guideline updates, new therapy indications, and rapidly shifting evidence all converge at a moment when physicians need clarity, not volume.
Yet across the industry, a familiar pattern persists: the right information is available, but not at the moment when a physician is actively making a therapeutic choice.
As Sarah Kurtz, President and COO at Partner Therapeutics, explains:
“Physicians want to be educated at the right time. They aren’t seeing these patients frequently enough to want to spend the mental energy until they have that patient in front of them.”
This reveals a key truth: clinicians aren’t disengaged, they’re overwhelmed by competing demands and constrained by the need to focus only on what’s immediately actionable. Precision medicine multiplies that tension.
The point of decision is where momentum is made or lost
The biggest barrier to therapy conversion is not unwillingness. It’s timing. Information that arrives outside the clinical decision window rarely shapes what happens next.
Peter Finlayson, VP of Marketing at Partner Therapeutics, highlights:
“It’s not because physicians don’t want patients to have those medications… it’s just that the information isn’t making it into the physician’s hands at that time.”
This challenge is not solved by additional awareness campaigns or more digital content. In fact, as Kurtz noted:
“You cannot solve everything with digital content alone.”
Digital channels play a role, but when decisions are nuanced, uncertain, or dependent on clinical interpretation, physicians often need something more grounded: a conversation with another expert.
Why peer‑to‑peer dialogue cuts through where traditional outreach doesn’t
Therapeutic decisions, especially those tied to biomarker‑driven care, aren’t just about data. They’re about confidence. Physicians need the space to ask questions, test assumptions, and understand how peers would navigate similar scenarios.
This is why relationships remain central to clinical momentum. These conversations aren’t promotional, they’re interpretive. They translate evidence into real‑world application and help physicians move forward with clarity under pressure.
The challenge is not persuading clinicians; it’s providing the right expert, at the right level, at the right moment.
Beyond individual clinicians: momentum depends on the whole care team
Another overlooked barrier to therapy conversion is fragmentation across the wider care ecosystem; pathologists, oncologists, specialist nurses, and diagnostic teams often operate with different timelines, pressures, and insights.
Supporting only one stakeholder rarely resolves delays; the entire care pathway influences whether therapy decisions happen with confidence. Targeting the whole care team, not just a single clinician, is critical to improving consistency and momentum.
The missing link: a way to activate timely, senior‑level, peer‑to‑peer education
The industry has long acknowledged the importance of clinical conversation, but operationalising it in a compliant, relevant, and timely way has remained difficult. Traditional outreach is too slow, too broad, or too detached from real clinical triggers.
What’s needed is an approach that delivers peer dialogue quickly, credibly, and within the therapeutic decision window, not weeks or months later.
Diaceutics Expert Exchange has become a trusted engagement engine
Expert Exchange is now a proven model for sparking timely, senior level, peer-to-peer clinical dialogue precisely when decisions are being made. By activating engagements within the critical diagnostic-to-treatment window, it drives meaningful conversations that build confidence, reduce uncertainty, and naturally supports smoother therapy conversion across the entire care team.
What Expert Exchange delivers:
Timely activation at the point of decision: Initiates expert-led discussions in as little as 48 hours during the exact moment when diagnostic results are being interpreted and treatment plans are being formed.
Whole-care-team engagement: Connects the full ecosystem of clinicians involved in the patient journey, reducing fragmentation and aligning decision-makers.
Contextual, case-based conversation: Engagements are triggered by real patient scenarios, enabling clinicians to explore questions that don’t fit into promotional materials.
Measured, reliable impact:
90% success rate in contacting target HCP institutions.
75% HCP engagement rate post-implementation.
“Being able to engage them at the right time in the right place allows us to make a real difference for patients.” —Kurtz
Talk to an expert today: Contact Us - Diaceutics
